David W. Evans VIKSNINS HARRIS & PADYS PLLP Practice Areas Pharmaceutical-chemical and biology patent prosecution and opinions Education University of Toronto, B.Sc. Chemistry and Biology, 1990 Bar Admissions United Sates Patent and Trademark Office, 1996 Canadian Intellectual Property Office, 1995 Professional Experience Viksnins Harris & Padys PLLP - Bloomington, Minnesota (February 2013 to present) Senior Patent Agent; Prepare and prosecute United States and international patent applications for pharmaceutical, chemical and biological inventions. Elan Pharmaceuticals, Inc. - South San Francisco, California (October 2011 – January 2013)
Senior Director. Managed all medicinal chemistry IP matters providing strategic advice to senior management. Prosecuted and drafted medicinal chemistry and biotechnology patent applications. Created patent term strategy for natural product drug candidate ELND005 in phII clinical trials for multiple indications, including, Alzheimer’s disease. Oversaw chemistry IP matters for collaborations with academia and industry partners. Performed freedom-to-operate, patentability, invalidity analyses. Negotiated license and collaboration agreements with potential partners. Supervised medicinal chemistry patent agent. Genentech Inc. - South San Francisco, California
Director. Head of small molecule IP practice group overseeing all medicinal chemistry IP matters. Created best practices standards for medicinal chemistry drafting, prosecution, diligence and transactions. Chaired quarterly IP reviews of medicinal chemistry projects for VP of Chemistry. Prosecuted and drafted medicinal chemistry and biotechnology patent applications for several small molecule compounds in clinical trials and marketed drugs Tarceva® and Everidge® as well as biologic drug Pulmozyme®. Prepared and prosecuted patent applications for diagnostic inventions including a commercial companion diagnostic for Tarceva®. Managed IP for several academic and industry collaborations. Managed Hatch-Waxman term extension process for Tarceva®, and Orange Book listings for Tarceva® and Everidge®. Managed European oppositions and appeals for marketed products Pulmozyme® and Everidge® as well as multiparty conflict proceedings in Canada for marketed HBV vaccines Engerix-B® and Recombivax HB® licensed to GlaxoSmithKline and Merck Frosst. Negotiated and drafted IP contracts and IP provisions for several academic and industry collaborations including collaborations with Array BioPharma which received Breakthrough Alliance Award of 2012 by Deloitte Recap and Forma Therapeutics which received 2011 Alliance of the Year by In Vivo Blog.
Cyprotex Plc - Macclesfield, UK
Board of Directors. Served as board member of publicly traded company that provides ADME, toxicity and pharmacokinetic screening services to pharmaceutical industry. Advised CEO and other board members on business initiatives and opportunities. Member of remuneration committee ISIS Pharmaceuticals Inc. - Carlsbad, California
Assistant Director. Managed IP portfolio for subsidiary IBIS Therapeutics, Inc. Prosecuted and drafted medicinal chemistry and biotechnology patent applications as well as for drug discovery platform dubbed “SAR by Mass Spec”. Also managed IP portfolio for joint venture with Elan Pharmaceuticals focused on discovery and development of delivery technologies for nucleic acid based therapeutics. Responsible for various opposition and interference proceedings and performed several freedom to operate, patentability and invalidity analyses and chemical structure searching.
BioChem Pharma Inc. - Laval, Québec
Manager. Managed group of patent agents and an attorney. Prosecuted and drafted medicinal chemistry and biotechnology applications, including, issuance of patent for marketed antiviral drug Emtriva®. Prepared and prosecuted vaccine patent applications for joint venture IAF Biovac, Inc. Managed opposition proceedings for marketed antiviral drug Epivir® in Europe, Norway, Australia and Japan. Oversaw interference proceedings for Emtriva®. Supported litigation team in defending infringement suit against Emory University regarding Epivir®. Supported orange book and Hatch-Waxman term extension process for Epivir®. Performed freedom to operate, patentability and invalidity analyses in support of numerous in-licensing initiatives. Allelix Biopharmaceuticals Inc. - Mississauga, Ontario (Nov 1991 – July 1995) Patent Analyst. Prosecuted medicinal chemistry and biotechnology applications relating to therapies for neurological disorders, radiodiagnostic imaging and microbial expression systems. Created and managed IP portfolio for radiodiagnostic joint venture Resolution Pharmaceuticals Inc. Performed numerous patentability and freedom to operate analyses. Became chemical structure searching expert. Canadian Intellectual Property Office - Hull, Québec
Technical Assistant. Performed prior art searching and analyses to support examination of Canadian patent applications. Reported to Division Chief of organic chemistry Examiners.
The Transition of Appalachia and the Transformation of Prosperity in the United States I. Overview Nearly two centuries ago, English economist David Ricardo put forth the “Theory of Comparative Advantage” to guide trade policy between nations. The theory posited that nations should specialize in the production of a small number of goods which they could manufacture efficiently,
BIJSLUITER: INFORMATIE VOOR GEBRUIKERS LIPITOR 10, filmomhulde tabletten 10 mg LIPITOR 20, filmomhulde tabletten 20 mg LIPITOR 40, filmomhulde tabletten 40 mg Lees goed de hele bijsluiter voordat u dit geneesmiddel gaat gebruiken Bewaar deze bijsluiter. Misschien heeft u hem later weer nodig. Heeft u nog vragen? Neem dan contact op met uw arts of apotheker. Geef dit geneesmiddel ni